RxDoctor Payments Data

Gunjan Mittal, MD

Family Medicine · Gilroy, CANPI 1679526578

Payments from drug & device makers

$5,594in general payments, 2019–2025

Across 326 payments — averaging $17.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$642
  • Mylan Specialty L.p.$632
  • Merck$596
  • Novo Nordisk$507
  • Boehringer Ingelheim$430
  • Johnson & Johnson$389
  • plus $2K from 25 others

What the payments were for

  • Food & beverage$5,46798%
  • Education$1272%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$5,594 in reported general payments places this provider in the 90th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$168,490
Medicare patients
300
Services billed
1,120

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide74$108,024
JardianceEmpagliflozin39$58,735
EliquisApixaban35$49,907
JanuviaSitagliptin Phosphate28$36,775
TradjentaLinagliptin32$32,590
Trelegy ElliptaFluticasone/Umeclidin/Vilanter30$30,628
TrulicityDulaglutide17$18,462
MyrbetriqMirabegron11$10,863
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog16$6,911
BelsomraSuvorexant14$6,644
Atorvastatin Calcium414$4,915
Gabapentin249$4,521
Novolog FlexpenInsulin Aspart14$3,977
Incruse ElliptaUmeclidinium Bromide12$3,607
Rosuvastatin Calcium102$3,336

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$507$108,02474 claims
Boehringer IngelheimJardiance, Tradjenta$430$91,32571 claims
PfizerEliquis, Paxlovid$342$52,65149 claims
MerckJanuvia, Belsomra$596$43,41942 claims
GSKTrelegy Ellipta, Incruse Ellipta$642$34,23542 claims
Lilly USA, LLCTrulicity$148$18,46217 claims
Astellas Pharma US IncMyrbetriq$42$10,86311 claims
AbbVieSynthroid$329$2,33029 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 10,533 family medicine providers in California.

Other family medicine in Gilroy

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →